two combination chemotherapy programs , acomla ( doxorubicin , cyclophosphamide , vincristine , methotrexate and leucovorin rescue , and cytarabine ) and chop-b ( cyclophosphamide , doxorubicin , vincristine , prednisone , and bleomycin ) , were evaluated in 29 prospective randomized patients with advanced diffuse histiocytic lymphoma .
C0055599
chop-b
C0010583
cyclophosphamide